ClassID:

20452

A61K31/548 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring

Recent Application in this class:
#1
20240374608
2024-11-14

USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

#2
20240009203
2024-01-11

COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

#3
20230057592
2023-02-23

USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

#4
20220331332
2022-10-20

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES

#5
20220280528
2022-09-08

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN REVERSING CANCER CHEMORESISTANCE

#6
20210145840
2021-05-20

T-cell lymphoma treatments

#7
20210128600
2021-05-06

Use of methylation inhibitors for the treatment of autoimmune diseases

#8
20210115066
2021-04-22

Dithio ETP derivatives

#9
20210106590
2021-04-15

Use of H3K9me3 modulation for enhancing cognitive function

#10
20190298732
2019-10-03

Pharmaceutical composition comprising epidithiodioxopiperazine compound or derivative thereof, or pharmaceutically acceptable salt thereof, for preventing or treating pulmonary hypertension

#11
20190211034
2019-07-11

Dithio ETP derivatives

#12
20190209577
2019-07-11

Use of H3K9me3 modulation for enhancing cognitive function

#13
20190117664
2019-04-25

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES

#14
20180305377
2018-10-25

Epidithiodioxopiperazine compound or its derivatives, and the use thereof

#15
20180289670
2018-10-11

COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER

#16
20180228808
2018-08-16

Use of H3K9me3 modulation for enhancing cognitive function

#17
20180155367
2018-06-07

ETP derivatives

#18
20180071251
2018-03-15

COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER

#19
20170246147
2017-08-31

COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER

#20
20170239261
2017-08-24

Epidithiodioxopiperazine compound or its derivatives, and the use thereof

#21
20170037058
2017-02-09

ETP derivatives

#22
20170027909
2017-02-02

COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER

#23
20150291622
2015-10-15

ETP derivatives

#24
20150284349
2015-10-08

EPIDITHIODIKETOPIPERAZINE COMPOUNDS, COMPOSITIONS, AND METHODS

#25
20150038496
2015-02-05

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES

#26
20150023907
2015-01-22

Reactivation of HIV-1 gene expression to treat persistent HIV infection

#27
20140271823
2014-09-18

Inhibition of hypoxia-inducible factor activity with extracts

#28
20140161785
2014-06-12

Verticillin A Inhibition of Histone Methyltransferases

#29
20130029927
2013-01-31

COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER

#30
20110028514
2011-02-03

Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators

#31
20100240581
2010-09-23

SELECTIVE PROTEASOME INHIBITORS FOR TREATING DIABETES

#32
20100069458
2010-03-18

COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER

#33
20090029974
2009-01-29

Tumor treatment with gliotoxin derivatives

#34
20080220056
2008-09-11

Treatment for liver disease

#35
20070015777
2007-01-18

Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart

#36
20050191302
2005-09-01

Treatment for liver disease